Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

D. Hong; A. Shergill; L. Bazhenova; B. C. Cho; R. Heist; V. Moreno; G. S. Falchook; M. Nagasaka; P. Cassier; B. Besse; D. W. Kim; S. Yoon; X. Le; T. Zhao; S. Atwal; E. Park; J. Lee

doi:10.1016/S0959-8049(22)00992-3

Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

D. Hong, A. Shergill, L. Bazhenova, B. C. Cho, R. Heist, V. Moreno, G. S. Falchook, M. Nagasaka, P. Cassier, B. Besse, D. W. Kim, S. Yoon, X. Le, T. Zhao, S. Atwal, E. Park, J. Lee

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S72
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)00992-3
State	Published - Oct 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0959-8049(22)00992-3

Cite this

Hong, D., Shergill, A., Bazhenova, L., Cho, B. C., Heist, R., Moreno, V., Falchook, G. S., Nagasaka, M., Cassier, P., Besse, B., Kim, D. W., Yoon, S., Le, X., Zhao, T., Atwal, S., Park, E., & Lee, J. (2022). Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. European Journal of Cancer, 174, S72. https://doi.org/10.1016/S0959-8049(22)00992-3

@article{3a14ffc9b0be4d7f92f895f408f2c40e,

title = "Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial",

author = "D. Hong and A. Shergill and L. Bazhenova and Cho, {B. C.} and R. Heist and V. Moreno and Falchook, {G. S.} and M. Nagasaka and P. Cassier and B. Besse and Kim, {D. W.} and S. Yoon and X. Le and T. Zhao and S. Atwal and E. Park and J. Lee",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)00992-3",

language = "English",

volume = "174",

pages = "S72",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

Hong, D, Shergill, A, Bazhenova, L, Cho, BC, Heist, R, Moreno, V, Falchook, GS, Nagasaka, M, Cassier, P, Besse, B, Kim, DW, Yoon, S, Le, X, Zhao, T, Atwal, S, Park, E & Lee, J 2022, 'Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial', European Journal of Cancer, vol. 174, pp. S72. https://doi.org/10.1016/S0959-8049(22)00992-3

Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET : Update from the Phase 1 SHIELD-1 trial. / Hong, D.; Shergill, A.; Bazhenova, L. et al.

In: European Journal of Cancer, Vol. 174, 10.2022, p. S72.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET

T2 - Update from the Phase 1 SHIELD-1 trial

AU - Hong, D.

AU - Shergill, A.

AU - Bazhenova, L.

AU - Cho, B. C.

AU - Heist, R.

AU - Moreno, V.

AU - Falchook, G. S.

AU - Nagasaka, M.

AU - Cassier, P.

AU - Besse, B.

AU - Kim, D. W.

AU - Yoon, S.

AU - Le, X.

AU - Zhao, T.

AU - Atwal, S.

AU - Park, E.

AU - Lee, J.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140474641&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00992-3

DO - 10.1016/S0959-8049(22)00992-3

M3 - Article

AN - SCOPUS:85140474641

VL - 174

SP - S72

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial

UN SDGs

Access to Document

Other files and links

Cite this